Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States

作     者：Pedro Luiz Serrano Usón Junior Daniel Ahn Mohamad Bassam Sonbol Tanios Bekaii-Saab Mitesh J.Borad Pedro Luiz Serrano Usón Junior;Daniel Ahn;Mohamad Bassam Sonbol;Tanios Bekaii-Saab;Mitesh J. Borad

作者机构：Hospital Israelita Albert EinsteinSão PauloBrazil Mayo Clinic Cancer CenterMayo ClinicPhoenixAZUSA 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2020年第9卷第4期

页      面：501-504页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：immunotherapy hepato biliary 

摘      要：Strategies involving immunotherapy and targeted therapies are emerging in the last years as valuable options for patients with hepatobiliary cancer(HBC)including hepatocellular carcinoma(HCC),gallbladder cancer(GBC),intrahepatic cholangiocarcinoma(ICC),and extrahepatic cholangiocarcinoma(ECC).